The study is meant to reveal whether a shorter treatment using a new combination of four different antibiotics could be as effective as the regular, longer treatment for tuberculosis (TB).If this research, named SimpliciTB, turns out successful, the treatment period for drug-sensitive tuberculosis could be reduced from six to four months, and the treatment of drug-resistant tuberculosis could go down from 18-24 months to six months.
Shorter treatmentA shorter treatment of TB brings several significant advantages. If the patient is cured faster, the period of contagiousness to others will also be shorter, which will also decrease the chance of the disease spreading. Additionally, it helps increase the patients’ compliance. The access to hospitals and proper medical care in the countries where TB occurs is often limited, which frequently puts the therapy compliance at stake in longer-term treatments. The shorter the treatment, the better the chances are of a patient finishing it. In the case of TB, completing the entire course of treatment is crucial. Mediocre therapy compliance can result in an increased resistance of the bacteria.
Radboud university medical center’s roleThe study is a global initiative of the TB Alliance. The Sub-Saharan African part of the study is carried out by PanACEA, a consortium of 16 institutes in 11 countries, coordinated by Martin Boeree and Rutger Spoor from the department of Pulmonary Diseases at Radboud university medical center. PanACEA received 12 million euros for this study, of which 1.6 million euros is made available to Radboud university medical center. Radboud university medical center takes on the management and medical monitoring and will work on the research capacity development of the African partners.
Capacity developmentThe continued development of African clinical research centers is a priority of the PanACEA consortium. Its aim is to get these centers to a higher level and keep them there and to have their clinical research meet the highest quality requirements, such as those of the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). This will put African centers in a position in which they will be able to lead future research. Aspects of capacity development include the development of infrastructure, admission facilities, laboratories and drugstores, but also the scientific support of PhD candidates and postdocs.
About tuberculosisTuberculosis is a prevalent infectious disease. About 2.3 billion people around the world have a latent infection, and 10 million new patients develop the active disease each year. Tuberculosis is caused by the Mycobacterium tuberculosis bacteria. These bacteria penetrate the cells and can become encased there. During this process, the tissue can get damaged, which leads to the disease. Tuberculosis generally affects the lungs but can also affect other parts of the body.
Related news items
Mark Janssen member of the Executive Board of Radboud university medical center from 15 March 202016 December 2019
Mr. Mark Janssen has been appointed by the Stichting Katholieke Universiteit as member of the Executive Board of Radboud university medical center (Radboudumc) from 15 March 2020, with the focus areas of finance and financial operational management, ICT, and construction.read more
In order to maximize quality of life in pediatric psoriasis reaching for clear skin is necessary12 December 2019
In JAMA Dermatology, Bruins et al showed that greatest improvement in quality of life was achieved with 90% improvement of the Psoriasis Area and Severity Index (PASI) and 90% decrease of affected body surface area in a large cohort of children with psoriasis.read more
Bart-Jan Kullberg appointed as Chair of Health Council12 December 2019
As of 1 January 2020, Bart-Jan Kullberg has been appointed as the Chairperson of the Health Council of the Netherlands.read more
Jelle Barentsz's trilogy of educational papers in European Urology12 December 2019
Recently, a trilogy of educational papers by our full professor Jelle Barentsz has been published in European Urology. The publications address what urologists need to know about prostate-MRI.read more
ERC Consolidator Grant for Bousema and Sechopoulos12 December 2019
Teun Bousema and Ioannis Sechopoulos each receive an ERC Consolidator Grant of around two million euros. This European research subsidy will enable them to carry out research for the next five years.read more